On Tuesday, TherapeuticsMD (TXMD) said that two studies of its investigational treatment for moderate to severe Vulvar Vaginal Atrophy (VVA) has shown “therapeutic advantages” over a drug from a rival manufacturer. TXMD stock climbed more than 5% on the news.
TXMD stock gained after the company said that studies that compared 10µg doses of its TX 12-004-HR drug to 10µg of Nordisk’s (NVO) Vagifem and doses of 25µg of TX 12-004-HR to the same dose of Vagifem revealed “substantially lower systemic estradiol exposure of TX 12-004-HR when compared to Vagifem.”
The company indicated that the studies’ results would be used to support the drug’s application to the U.S. Food and Drug Administration for approval in the treatment of VVA in postmenopausal women.
TX 12-004-HR also produced half the concentration of a certain vaginal hormone as Vagifem. Vaginal hormone therapy side effects may be linked to higher concentrations of the hormone.
TXMD stock closed a $5.66 a share on Monday. TXMD stock has gained more than 74% over the past year.